Related Experiment Videos
Indoprofen in juvenile chronic arthritis
Clinical and Experimental Rheumatology
|January 1, 1985
Summary
Indoprofen effectively treated juvenile chronic arthritis in children, outperforming aloxiprin in reducing swelling and pain. This non-steroidal anti-inflammatory drug demonstrated good tolerability for pediatric patients.
Area of Science:
- Pediatric Rheumatology
- Pharmacology
- Clinical Trials
Background:
- Juvenile chronic arthritis (JCA) is a debilitating condition in children.
- Current treatments for JCA have limitations in efficacy and tolerability.
- Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for symptom management.
Purpose of the Study:
- To compare the efficacy and safety of indoprofen versus aloxiprin in children with JCA.
- To evaluate the impact of indoprofen on key JCA symptoms like swelling, pain, and joint function.
Main Methods:
- A comparative study involving children diagnosed with juvenile chronic arthritis.
- Patients received either indoprofen (10-12 mg/kg) or aloxiprin (80 mg/kg).
- Outcomes assessed included soft tissue swelling, joint limitation, pain, morning stiffness, and grip strength.
Main Results:
- Indoprofen showed significant superiority over aloxiprin in reducing soft tissue swelling and joint limitation.
- Indoprofen was effective in alleviating pain and morning slowness.
- Improvements in grip strength were observed with indoprofen treatment.
- The drug was well-tolerated by the pediatric participants.
Conclusions:
- Indoprofen is a safe and effective treatment option for children with juvenile chronic arthritis.
- Indoprofen offers significant benefits over aloxiprin for managing JCA symptoms.
- Further research may explore long-term efficacy and safety profiles.